OSE Immunotherapeutics has announced that Marc Le Bozec will transition form interim CEO (which was effective from 2 October 2025) to permanent CEO (effective immediately). The decision was made based on a detailed review of internal and external candidates, and upon recommendation of the Nomination and Compensation Committee. Marc Le Bozec is committed to leading the company in its goals to deliver novel immunotherapies in the fields of immuno-oncology and immuno-inflammation, with a focus on precision medicine and patient centric clinical development.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment